Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109.
- DOI
- 10.1016/j.ctarc.2026.101220
- Published
- 2026
- Container
- Cancer treatment and research communications
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ctarc.2026.101220,
title = {Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109.},
author = {Lee JW and Jin X and Bogdan S and Abou-Alfa A and Chang J and Rafizadeh M and Kang EC and Garcia C and Zhou XK and Saxena A},
year = {2026},
journal = {Cancer treatment and research communications},
doi = {10.1016/j.ctarc.2026.101220},
url = {https://doi.org/10.1016/j.ctarc.2026.101220}
}RIS
TY - JOUR TI - Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109. AU - Lee JW AU - Jin X AU - Bogdan S AU - Abou-Alfa A AU - Chang J AU - Rafizadeh M AU - Kang EC AU - Garcia C AU - Zhou XK AU - Saxena A PY - 2026 JO - Cancer treatment and research communications DO - 10.1016/j.ctarc.2026.101220 UR - https://doi.org/10.1016/j.ctarc.2026.101220 ER -
APA
JW, L., X, J., S, B., A, A., J, C., M, R., EC, K., C, G., XK, Z., & A, S. (2026). Corrigendum to Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression, Cancer Treatment and Research Communications 46 (2026) 101109.. Cancer treatment and research communications. https://doi.org/10.1016/j.ctarc.2026.101220
Source records
- pubmed · retrieved 2026-09-26T09:38:59.495Z